These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
    Author: Kitamura Y, Yoshii H, Nishimoto K, Shinchi Y, Tokonabe S, Takao M, Daido Y.
    Journal: Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578.
    Abstract:
    Tyrosine kinase inhibitors such as sorafenib and axitinib were developed to treat malignancies, including stage IV renal cell carcinoma. Recently, we experienced a patient with pancreatic side effects from both sorafenib and axitinib. We report this case and include a discussion of the literature.
    [Abstract] [Full Text] [Related] [New Search]